Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. - Wikidata - awgldk - TriplyDB

Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.

Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.

http://www.wikidata.org/entity/Q53188675

about

Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction Prognostic significance of volume-based PET parameters in cancer patients.Bioenergetic analysis of ovarian cancer cell lines: profiling of histological subtypes and identification of a mitochondria-defective cell line.Prognostic Significance of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Operable Primary Breast Cancer.Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer.Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma.Positron Emission Tomography (PET) in Oncology FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1.Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.Total Lesion Glycolysis Using ¹⁸F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer.Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy.Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients Identification of Metabolic Biomarkers Using Serial 18F-FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian Cancer Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary.PET/CT versus MRI for diagnosis, staging, and follow-up of lung cancer.Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma.Metabolic Tumor Volume by 18F-FDG PET/CT Can Predict the Clinical Outcome of Primary Malignant Spine/Spinal Tumors.Molecular imaging in ovarian cancer.An update on the role of PET/CT and PET/MRI in ovarian cancer.Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.Guidelines for quality control of PET/CT scans in a multicenter clinical study PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients.Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer.Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma.Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma.Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma.Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer.Diagnostic imaging using positron emission tomography for gynecological malignancy.Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.What's New in Imaging for Gynecologic Cancer?The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Nasopharyngeal Carcinoma Patients after Comprehensive Therapy.

P2860

Q26786610-3C46FE4A-5D53-44BE-92B0-2CF8E5B88673 Q27687836-F83D9516-69DA-4F59-8583-40A3F1C3FC0F Q33655175-9083962D-6125-4CED-8C56-7ECC55465D00 Q33704628-992D46F4-D811-46D3-B126-675E44BA129F Q33704656-C22FED56-E068-481B-A256-7EE3B2D89A90 Q33735128-1013DF44-0738-4DF0-9790-947C7697430A Q34774840-D4118764-C818-4916-B261-B169C3DB4BC3 Q35043725-E3BDA671-F8C3-4169-BF6F-F978E6EA1581 Q35761121-C4AA4221-B301-4227-8487-3CA5C1898864 Q35857307-AAF39B10-82CF-4BE2-B4B1-16CDCC3725A9 Q35961361-ADDC3C9E-7F0A-4211-8326-6E6CBEB2B0DA Q35983497-C92B87E4-12FC-4064-B5AF-1549ABCBAEEB Q36029023-0B882FAD-7928-47F5-BF86-2DDD386FF767 Q36060090-8429118D-7388-4306-B6D3-7CFE9C6AF71F Q36132602-15593591-DE7A-4BB3-94A5-BC36A17A4C01 Q36461563-4AFE760E-850C-482F-B2A8-1F932EDC1A9C Q36663805-3E47F419-478B-4713-B4F0-48F9C399A0E6 Q36801193-8541EE59-5670-46DF-8573-531F38A260E3 Q37153528-DFA4A8C5-111D-4040-A2CC-95E5872A1D92 Q37715868-48EA7658-E61E-46C0-9F69-007174B31F17 Q37724181-C986A885-9314-48F4-B1FF-DC9B6B8DC8AD Q38264614-0F9F06B4-74AB-4907-B0EC-70AFDDD150E6 Q38417118-3C6D23AE-956C-4781-BEC8-8FF125EAE5C9 Q38602774-5E7E3997-83E2-4FE2-BC70-B4E0F5B116AE Q38824319-C8AF9B97-4C4E-41B0-BEEE-F58ADD5BEC8A Q39127714-2EEF4FF3-2135-4AF1-A051-98884ABE4360 Q40527607-912ACAE4-00B2-40BB-9254-756BCC9FF5D0 Q41683890-29195422-C5BA-4806-9882-CD53998CF393 Q42721856-10D0C4DE-BEF0-43FB-B77C-2ABC6A8B490E Q43526833-E8DCB98D-E39E-46D5-A57C-518813CB9D0E Q45849759-4B0C0936-1C8B-4043-8E29-0A28A46A4AA5 Q45917673-DC54682D-E0CD-41BC-A7CE-350107943571 Q46284024-670CFDE0-D653-4FB5-A736-D760D4385C07 Q46506999-ED4EF8AA-FCAD-42F8-8883-03EC301B134F Q47279109-B2FF2BAB-C272-4937-87A1-0A7392C6B696 Q48105266-942F13AE-979A-4E83-A604-98449E2E8F61 Q49147470-DF33BBF2-01E4-4BDE-AF3E-536C6C079EB3 Q50145613-1CE3E86F-27AE-4132-B371-C927E095E699 Q53027673-E08C568C-A39F-4788-B8AF-611EED6A8373 Q55255644-26A13782-67C5-489E-8465-32639FB2E2DC

P2860

Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.

http://www.wikidata.org/entity/Q53188675

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Prognostic value of preoperati ...... ith epithelial ovarian cancer.

@en

Prognostic value of preoperati ...... ith epithelial ovarian cancer.

@nl

type

label

Prognostic value of preoperati ...... ith epithelial ovarian cancer.

@en

Prognostic value of preoperati ...... ith epithelial ovarian cancer.

@nl

prefLabel

Prognostic value of preoperati ...... ith epithelial ovarian cancer.

@en

Prognostic value of preoperati ...... ith epithelial ovarian cancer.

@nl

P1433

Q53188675-EF7F5F75-6003-4D50-B182-7DA093F61CD4

P1476

Q53188675-FB7A8F75-8583-4B76-A7DC-F48D7ECD9FDF

P2093

Q53188675-03FBF7F0-ECD7-41E7-8BB1-5ABC47C42C0E

Q53188675-07DB017A-A897-4890-9480-E9BCC149CC13

Q53188675-7FA940C3-37B5-47B0-8D5F-51A5FF2E0CA3

Q53188675-AE78A55F-8AE2-47D6-B1D2-EB394E2462E3

Q53188675-B00235F0-EFEE-41DB-B634-C66E420BF4C8

Q53188675-D5BF7A6C-0270-4A9F-B5EB-3BA55D961B1E

Q53188675-E40C8F8A-900B-43D7-8952-C97A4D733F9C

P2860

Q53188675-0D179933-C69B-4973-85EE-793E8818AC1A

Q53188675-28268243-2D9F-40BE-8102-9383D04F49D3

Q53188675-2B5DAD72-BA79-45E9-B440-94147548D625

Q53188675-38A273CB-6554-4B8B-B306-1DB245ADF213

Q53188675-394B4436-DA55-48B8-9C81-916BD71414A6

Q53188675-477F7890-C830-443D-A9CE-360437B8D9BE

Q53188675-50F2C01A-19B4-46E5-8476-CF940020CBA4

Q53188675-51463E12-5F3C-4815-A897-4AFF6D994846

Q53188675-6293F7AC-3614-4E92-917C-C34B754EFCD5

Q53188675-65FE4001-98D5-4290-A490-9FE36524D8BA

P2888

Q53188675-04778EE9-E7ED-4801-BD35-1A8192DFFA06

P304

Q53188675-E90F2253-2FFB-4C3C-B20F-EDE825B6397A

P31

Q53188675-9E038B43-120F-4269-ACE7-924629EC36BA

P356

Q53188675-8B89E691-429C-4ED9-9988-6282A35A3EE3

P433

Q53188675-0C447A21-F5E0-4494-9E97-C7790B54E0B9

P478

Q53188675-BA12DD41-7B4B-4E9B-9483-BC6A92BDA28C

P50

Q53188675-8ECC0E13-E0B0-4E55-B5D3-213DFA78B0E1

P577

Q53188675-3235C7AF-9419-4371-96E6-3736562EABCD

P6179

Q53188675-F6A2E5D5-0DD4-472D-9EC9-EB8E50733055

P698

Q53188675-8BBB2D2C-B037-42E3-A6EB-A230A3B1765B

P921

Q53188675-9F9FC813-CE81-4AAE-BA8E-C6383D4B8529

P356

S10434-011-2153-X

P1433

Annals of Surgical Oncology

P1476

Prognostic value of preoperati ...... ith epithelial ovarian cancer.

@en

P2093

Hyun Hoon Chung

http://www.w3.org/2001/XMLSchema#string

Hyun Woo Kwon

http://www.w3.org/2001/XMLSchema#string

June-Key Chung

http://www.w3.org/2001/XMLSchema#string

Keon Wook Kang

http://www.w3.org/2001/XMLSchema#string

Noh-Hyun Park

http://www.w3.org/2001/XMLSchema#string

Soon-Beom Kang

http://www.w3.org/2001/XMLSchema#string

Yong-Sang Song

http://www.w3.org/2001/XMLSchema#string

P2860

A hospital-based case-control study of identifying ovarian cancer using symptom index.

Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.

Epidemiological characteristics of ovarian cancer in Korea.

Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT.

Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.

Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.

Role of PET/CT in ovarian cancer.

Basic principles of ROC analysis.

Development of an ovarian cancer symptom index: possibilities for earlier detection.

Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.

P2888

s10434-011-2153-x

P304

1966-1972

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-011-2153-X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024196126

http://www.w3.org/2001/XMLSchema#string

P698

22124757

http://www.w3.org/2001/XMLSchema#string

P921